Research programme: cancer therapeutics - Piramal Healthcare

Drug Profile

Research programme: cancer therapeutics - Piramal Healthcare

Alternative Names: Microbial leads - Piramal Healthcare; PI3 kinase - Piramal Healthcare

Latest Information Update: 16 Jul 2016

Price : *
* Final gross price and currency may vary according to local VAT and billing address.

At a glance

  • Originator Piramal Healthcare
  • Developer Piramal Enterprises
  • Class
  • Mechanism of Action 1 Phosphatidylinositol 3 kinase modulators
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No

Highest Development Phases

  • No development reported Cancer

Most Recent Events

  • 16 Jul 2016 No recent reports of development identified for preclinical development in Cancer in India (PO, Tablet)
  • 01 Jan 2008 Early research in Cancer in India (unspecified route)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top